Towards Automated Manufacturing for Cell Therapies

Area of Science:

• Cellular and Molecular Medicine
• Biotechnology Manufacturing
• Process Engineering

Background:

• The cell therapy pipeline is rapidly expanding, necessitating robust manufacturing capabilities for commercial viability.
• Securing long-term visions for funding and treatment success requires addressing manufacturing challenges.

Purpose of the Study:

• To provide an overview of manufacturing automation in cell therapy.
• To discuss strategic drivers for automation implementation.
• To explore automation considerations for patient-specific cell therapy (PSCT) and off-the-shelf cell therapy (OTSCT).

Main Methods:

• Literature review of automation strategies in cell therapy manufacturing.
• Analysis of unique challenges in PSCT versus OTSCT automation.
• Discussion of practical implementation considerations.

Main Results:

• Automation is a key tactic to address quality, cost of goods, scale, and sustainability in cell therapy manufacturing.
• Distinct automation approaches are required for PSCT (one lot per patient) and OTSCT (one lot for multiple patients).
• Practical considerations for automation implementation are essential for successful adoption.

Conclusions:

• Automation is critical for enabling commercially viable cell therapy manufacturing.
• Tailored automation strategies are needed for different cell therapy modalities (PSCT vs. OTSCT).
• Addressing automation challenges is fundamental for the future of cell therapy development and accessibility.